

1 **Constitutively elevated levels of SOCS1 suppress innate responses in DF-1 immortalised**
2 **chicken fibroblast cells**

3

4 **Giotis ES¹, Ross CS², Robey RC¹, Nohturfft A², Goodbourn S² and Skinner MA^{1*}**

5

6 *¹Section of Virology, School of Medicine, St Mary's Campus, Imperial College London W2 1PG*

7 *²Institute for Infection and Immunity, St George's, University of London, London SW17 0RE, UK*

8

9

10

11

12

13

14

15

16 *Correspondence to MAS (email: m.skinner@imperial.ac.uk).

17

18

19

20

21

22

23

24

25

26 **Abstract**

27 The spontaneously immortalised DF-1 cell line is rapidly replacing its progenitor primary chicken
28 embryo fibroblasts (CEFs) for studies on avian viruses such as avian influenza but no
29 comprehensive study has as yet been reported comparing their innate immunity phenotypes. We
30 conducted microarray analyses of DF-1 and CEFs, under both normal and stimulated conditions
31 using chicken interferon- α (chIFN α) and the attenuated infectious bursal disease virus vaccine
32 strain PBG98. We found that DF-1 have an attenuated innate response compared to CEFs. Basal
33 expression levels of *Suppressor of Cytokine Signalling 1* (chSOCS1), a negative regulator of cytokine
34 signalling in mammals, are 16-fold higher in DF-1 than in CEFs. The chSOCS1 “SOCS box” domain
35 (which, in mammals, interacts with an E3 ubiquitin ligase complex) is not essential for the
36 inhibition of cytokine-induced JAK/STAT signalling activation in DF-1. Overexpression of SOCS1 in
37 chIFN α -stimulated DF-1 led to a relative decrease in expression of interferon-stimulated genes
38 (ISGs; MX1 and IFIT5) and increased viral yield in response to PBG98 infection. Conversely,
39 knockdown of SOCS1 enhanced induction of ISGs and reduced viral yield in chIFN α -stimulated DF-
40 1. Consequently, SOCS1 reduces induction of the IFN signalling pathway in chicken cells and can
41 potentiate virus replication.

42

43

44

45

46

47

48

49

50

51 **Introduction**

52 The increasing occurrence of zoonotic infections attributable to avian viruses such as avian
53 influenza viruses H5N1 and H7N9, West Nile virus, Japanese encephalitis virus, eastern (and
54 western) equine encephalitis viruses, as well as avian *Salmonella* and *Campylobacter* bacterial
55 species, has highlighted the need for well-established avian experimental models of infection and
56 immunity. Limitations in the usage of embryonated chicken eggs (or chick embryo fibroblasts -
57 CEFs), due to costly, time-consuming production processes or supply problems, hinder scaled-up
58 procedures such as vaccine manufacturing, while alternative avian or mammalian cell substrates
59 have several drawbacks, particularly due to restricted host- and receptor-specificity¹⁻³.

60 CEFs have largely replaced embryonated eggs for vaccine production and viral infection studies as
61 they are safe, proliferate well, are surprisingly consistent in terms of their expression **profiles⁴. and**
62 provide high pathogen yield, albeit with increased cost, laborious manufacturing process and
63 limited life span^{1,3}. The requirement for avian cell lines in diagnosis and research, as well as for
64 vaccine production, has shifted the focus of the scientific community towards deriving continuous
65 cell lines that could eliminate recurring costs associated with CEFs. Avian cells are difficult to
66 immortalise and new cell lines have been primarily developed using tumorigenic viruses,
67 transforming oncogenes, or oncogenic chemicals, rendering them less suitable for vaccine
68 production^{2,5}. Embryonic stem cell lines such as duck EB66 and chicken EB14 are being evaluated
69 for use in the vaccine industry, with the advantages that they are relatively genetically stable, have
70 unlimited life span and circumvent disadvantages associated with tumorigenic cell lines^{6,7}. Despite
71 the availability of these new cell lines, large animal and human vaccine processes still rely heavily
72 on CEFs as a first choice or as a certified alternative substrate for the propagation of many
73 commercially available clinical vaccines such as those for measles and mumps (for example, MMR II,
74 Merck), tick borne encephalitis (FSME IMMUN, Baxter) and rabies (RabAvert, Novartis)^{3,8}.

75 An alternative to CEFs is the chicken fibroblast cell line UMNSAH/DF-1 (DF-1), which is gradually
76 becoming a standard avian cell substrate. Derived originally from 10-day-old East Lansing Line 0
77 (ELL-0) eggs⁹, DF-1 is possibly the only readily available, spontaneously-immortalised, endogenous
78 virus-free avian cell line that exhibits high transfection efficiency and a high proliferation rate while,
79 at the same time, supporting satisfactory propagation of a broad range of avian viruses^{10,11}. DF-1
80 cells have been extensively used for the propagation and/or study of various avian viruses,
81 including avian influenza virus such as the highly pathogenic Eurasian H5N1 and H7N1 subtypes¹²,
82 avian leukosis virus¹⁰, avian sarcoma leukosis virus (ASLV)¹³, fowlpox virus¹⁴, Marek's disease
83 virus¹⁵, infectious bursal disease virus (IBDV)¹⁶ and avian metapneumovirus¹⁷. Phenotypically, DF-
84 1 cells are characterized by a suppression of cell death pathways (consistent with their immortal
85 hyperproliferative phenotype¹⁸), dysfunctional cell proliferation-related genes p53 and E2F-1, as
86 well as defective antioxidant gene expression^{11,19,20}.

87 Compared with their progenitor CEFs, DF-1 have enhanced growth potential¹⁸, smaller
88 morphology²¹ and can support comparable or even higher replication of IBDV, ASLV, avian
89 influenza and some other viruses^{12,13,16}. High viral replication in DF-1 implies that viruses (even
90 attenuated vaccine strains) are not efficiently restricted by the cells' antiviral innate immunity. This
91 is despite reports that DF-1 readily express known interferon-stimulated genes (ISGs), potentially
92 with antiviral activity, following stimulation with recombinant chIFN- α or, to lesser extent, with
93 recombinant chIFN- β ²². We hypothesised that the type I IFN-induction and/or signalling pathways
94 in DF-1 might be dysregulated compared to CEF, compromising the innate response to viruses and
95 thereby permitting their replication. However, although the constitutive gene expression profile of
96 DF-1 relative to CEF has been compared¹⁸, their induced innate responses have not been compared
97 directly.

98 Here we demonstrate, using microarrays, that DF-1 do indeed mount an operational type I IFN
99 response following stimulation with recombinant chIFN- α or infection with a highly immunogenic
100 attenuated vaccine strain of IBDV (PBG98) that was employed as a model pathogen to evaluate IFN
101 induction and signalling. However, the relative number and expression levels of ISGs in DF-1 cells
102 displayed an attenuated innate response compared with primary CEFs. Importantly, in DF-1 we
103 observed that the regulatory ISG, SOCS1 (*Suppressor Of Cytokine Signaling*), was barely induced by
104 IBDV infection or by IFN (by only 1.8 and 2.5 fold, respectively), which is to far lesser extents (23
105 and 8 fold less, respectively) than in CEFs. We attributed this to the high constitutive level of
106 expression of SOCS1 we observed in DF-1. Kong *et al.*¹⁸, who published after conduct and analysis of
107 our microarrays, also observed that constitutive levels of expression of SOCS1 in DF-1 were
108 elevated relative to CEFs but they did not investigate IFN-stimulated gene expression and could
109 therefore not appreciate the scale and significance of that observation.

110 We further demonstrate that the elevated constitutive expression of SOCS1 in DF-1 cells in turn
111 attenuates IFN signalling and antiviral immunity. We also found that viral replication could be
112 facilitated or impeded by transient up or down modulation, respectively, of SOCS1 in CEFs and DF-1
113 cells, respectively.

114 Although we have reservations concerning the comparison of the DF-1 cell line with the relatively
115 mixed population of cells represented by CEFs, this study addresses the practical issue that in the
116 past there have been (and continue to be) many studies of virus infection and innate responses in
117 CEFs but that increasingly the same studies are more likely performed with DF-1. Our results will
118 help researchers compare and understand those two types of study.

119

120 **Results**

121 *Microarray analysis identified enhanced cell proliferation as well as repressed inflammation- and*
122 *apoptosis-related gene expression in DF-1 cells.*

123 Comparison of untreated CEFs and DF-1 cells identified 856 transcripts that are more highly
124 expressed in DF-1 cells than in CEFs, and 1747 transcripts that are more highly expressed in CEFs
125 than in DF-1 cells (Supplementary Table 1). These data, obtained using the 35K Affymetrix Chicken
126 Genome Array, are consistent with those obtained using the 44K 60-mer oligonucleotide Agilent
127 chicken microarray, as reported by Kong *et al.*¹⁸ after we had already obtained and processed our
128 results.

129 The resulting lists of differentially expressed transcripts were further analysed by the MetaCore™
130 pathway enrichment analysis tool (Thomson-Reuters). The top 10 ranking canonical pathway maps
131 associated with the upregulated transcripts in DF-1 cells are listed in Table 1. Upregulated
132 transcripts were associated with critical processes that control progress through the eukaryotic cell
133 cycle and the initiation of mitosis, such as spindle assembly and chromosome segregation that
134 function at the G2-M transition (CDK1, cyclin A, importin-alpha, KNSL1), the anaphase-promoting
135 complex (CDC20, Aurora-A, Nek2A CDK1, CKS1) activity, cell proliferation (BubR1) and DNA repair
136 (BRCA1, BRCA2). Transcripts that were overexpressed in CEFs relative to DF-1 cells (Table 2) were
137 associated with extracellular matrix (ECM) and cytoskeleton remodelling involved in embryonic
138 development (MMP-9, MMP-13, TIMP3, PLAU, Keratin-5, -7, -14, -19), cell adhesion (E-cadherin,
139 VE-cadherin) and signalling cascades (FGF, plasmin, TGF-β). In addition, many inflammation-
140 associated transcripts (IL-6, IL-18, IL-1R1, COX2, TLR2, TGF-β2) and apoptosis regulators (caspase-
141 3, lamin A/C, bCL2) were found to be repressed in DF-1 cells compared with CEFs.

142 Functional categorization by Gene Ontology (GO) using the Panther classification database²³
143 identified that the GO Biological Process most significantly overrepresented amongst upregulated
144 (and the second most significant amongst downregulated) transcripts in untreated DF-1 relative to

145 CEF was related to metabolic processes (with 24 and 22% of total transcripts upregulated and
146 downregulated, respectively). Most of the transcripts were involved in energy metabolism and the
147 regulation of metabolic processes in mitochondria. Innate and immune response-related
148 transcripts constituted 3 and 6% of the total transcripts upregulated and downregulated,
149 respectively, between the immortalized and primary cells (Fig. 1A).

150 Transcription factor analysis of array data for untreated DF-1 and CEFs, using the Metacore
151 algorithm, identified a statistical overrepresentation ($P < 0.001$) of transcription factor binding
152 sites for the transcription factor CREB1 (cAMP responsive element binding protein 1), which
153 regulates diverse cellular responses including: proliferation, survival, differentiation and s response.
154 Other enriched motifs included *c-myc* (involved in cell growth and apoptosis), STAT-related
155 transcription factors, NF- κ B-related transcription factors (c-Rel, NF-AT1 & 2, p50, p52, and p65)
156 and the cell proliferation-related E2F1 (E2F transcription factor 1), SP-1/3 (Sp1/3 transcription
157 factors), and p53 (Supplementary Table 2).

158

159 *Compared with CEFs, DF-1 cells display an attenuated response to chIFN- α and IBDV infection*

160 In order to characterize and compare the innate response of CEFs and DF-1, we profiled the cells in
161 two ways: (i) by treating them with recombinant chIFN- α (1000 units ml⁻¹) for 6h, and (ii) by
162 infecting cells with PBG98 (MOI 5, 16h). Gene expression was analyzed by DNA microarrays and
163 qRT-PCR. ChIFN- α initiated strong induction of ISG expression (213 transcripts) in CEFs while the
164 response in DF-1 cells was attenuated, with induction of 164 ISGs (of which 89 were regulated in
165 common with CEFs) (Fig. 1B). Levels of induced expression of ISGs (i.e. Mx1, RSAD2, LYG2) were
166 consistently lower in DF-1 cells than in CEFs (Fig. 1B, Supplementary Table 1 and unpublished).
167 IBDV PBG98 infection initiated robust regulation of host transcript expression in CEFs, with 345
168 transcripts upregulated and 138 transcripts downregulated. In comparison, DF-1 cells showed

169 limited transcript induction (and no transcript repression) with 30 transcripts upregulated (i.e.
170 chIFN- β , IL6, CCL20, Fig. 1C), 27 of which were regulated in common with CEFs. Comparison of the
171 two cell lines shows different subsets of virus-induced transcripts and ISGs (Venn diagrams in Fig.
172 1B and C, and Supplementary Table 1).

173 Hierarchical clustering was performed for the 45 most highly expressed ISGs (ranked according to
174 the chIFN- α -stimulated CEFs transcript list) in combined data for all microarray comparisons using
175 the heatmap function in R (Fig. 1D). This clustering separated the samples into three main groups.
176 The first two subsets included: (i) ISGs with high expression in all treatments but lower basal
177 expression in untreated DF-1 cells compared with CEFs (Mx1, ISG12-2, RSAD2, LOC418700) and (ii)
178 a single ISG (IFIT5) that is highly expressed in all conditions but relatively unchanged in untreated
179 cells. Most ISGs fell into a third intermediary subset with expression patterns that indicate
180 attenuated expression in DF-1 compared with CEFs for all treatments but wide ranging basal
181 expression levels. Amongst ISGs, SOCS1 was notable in having the most highly upregulated basal
182 level in DF-1 (whereas it is 44th in the list of ISGs ranked according to IFN-induction in CEFs). It is
183 expressed in untreated DF-1 at levels 16-fold higher than in CEFs. Stimulation of CEFs with IFN, or
184 by IBDV infection, raised the expression levels of SOCS1 to those equivalent to DF-1 at basal levels
185 (Fig. 1E).

186

187 *Correlation analysis between microarray by qRT-PCR analyses*

188 Microarray data were validated by quantifying the mRNA abundance of 10 selected transcripts
189 (SOCS1, Mx1, IFN- β , TGF β ₂, IL15, IRF7, IRF8, VCAM1, C15ORF48 and STAT1), using qRT-PCR (Fig.
190 2). These genes were selected among those found significantly regulated in at least one microarray
191 comparison, and identified as significant due to their potential importance in the innate response of
192 the cells. Pearson's correlation test was performed to test for pairwise correlations among the two

193 methods on all 10 genes. The correlation coefficients (r) for all comparisons were over 0.97,
194 indicating the high reproducibility of results with either method. We note that IFN- β was not
195 induced by exogenous IFN- α in either CEFs (at least as detected by microarray) or DF-1 cells but it
196 was induced (to a lesser extent in DF-1 cells than in CEFs) by infection with IBDV, clearly
197 demonstrating the requirement for a second signal (along with IRF3 activation) for induction of the
198 IFN- β promoter.

199

200 *siRNA-mediated knockdown and overexpression of SOCS1 suggest that SOCS1 promotes IFN response*
201 *attenuation in DF-1 cells*

202 To understand the effects of chicken SOCS1 on the innate response, DF-1 cells 42h post-transfection
203 with siRNA specific for SOCS1 (siSOCS1) or control siRNA (siControl) were stimulated with chIFN- α
204 for a further 6h. RNA was then collected and the expression of ISGs (SOCS1, Mx1, IFIT5) was
205 monitored by qRT-PCR. The expression of chicken SOCS1 at 48 hours post-transfection (hpt) in
206 cells transfected with siSOCS1 was reduced to 50% relative to that in mock DF-1 and DF-1
207 transfected with siControl (Fig. 3A); the siSOCS1 also efficiently limited the response of endogenous
208 SOCS1 to chIFN (Fig 3A). Knock-down efficiency of siSOCS1 was also confirmed by western blot
209 using a Flag antibody in cell lysates from DF-1 co-transfected with siSOCS1 and a flag-tagged SOCS1
210 construct in pEF.pLink2 (Fig. 3H). Knocking down endogenous SOCS1 in chIFN- α -stimulated DF-1
211 cells led to an increase of Mx1 and IFIT5 mRNA expression compared with mock-treated cells and
212 cells transfected with siControl (Fig. 3B and 3C).

213 Next, we over-expressed HA-tagged SOCS1, using an expression plasmid, with and without chIFN- α ,
214 and examined the expression of SOCS1, Mx1 and IFIT5 using qRT-PCR. Overexpressing SOCS1 in
215 chIFN- α -stimulated DF-1 cells led to a significant decrease of Mx1 and IFIT5 mRNA induction

216 compared with mock-treated cells and cells transfected with the empty plasmid (Fig. 3E and 3F).
217 Western blotting confirmed the expression of the HA-tagged fusion SOCS1 protein (Fig 3G).

218

219 *The SOCS box of chicken SOCS1 is not essential for blocking JAK/STAT signalling*

220 As a complementary approach to demonstrating the role of SOCS1 by siRNA knockdown, we sought
221 to abrogate its activity by deletion of known critical regions. In mammals, SOCS1 is known to
222 interfere with the JAK-STAT signalling pathway²⁴. SOCS1 is one of the 8 members of the suppressor
223 of cytokine signalling (SOCS) and CIS family of intracellular proteins (CIS, SOCS1, SOCS2, SOCS3,
224 SOCS4, SOCS5, SOCS6 and SOCS7)²⁴. Each of these proteins has: (i) an amino-terminal domain of
225 variable length and sequence, (ii) a kinase inhibitory region (KIR)²⁵, (iii) a central SH2 domain and
226 (iv) a carboxy-terminal 40-amino acid module known as the SOCS box²⁵. The SH2 domain of SOCS1
227 binds to the activation loop of JAKs. SOCS1 and SOCS3 have been shown to inhibit JAK tyrosine
228 kinase activity directly through their KIR domain^{26,27}. The SOCS box interacts with elongin B and
229 elongin C, cullins and the ring-finger domain-only protein RBX2, which recruits E2 ubiquitin
230 transferase and mediates degradation of the proteins with which CIS-SOCS proteins associate
231 through the SH2 domain and/or N-terminal regions²⁷.

232 We therefore generated a deletion mutant for the SOCS box region of chicken SOCS1 (Fig. 4A) and
233 tested its ability to modulate IFN-signalling using two luciferase reporter constructs (pchMx-lucifer
234 and pchViperin-lucifer) for the IFN-responsive promoters from chicken ISGs Mx1 and viperin,
235 respectively (Fig. 4B). DF-1 cells were transiently co-transfected with pchMx-lucifer or pchViperin-
236 lucifer, a beta-galactosidase reporter as well as expression plasmids for wild type SOCS1 or the
237 SOCS1 deletion mutant, or the empty expression plasmid (pEF-FLAG.pL2). Promoter activity in cells
238 transfected with pEF-FLAG.pL2 was induced after chIFN- α -treatment by approximately 18-fold
239 (Mx1) and 14-fold (Viperin). Induction of the ISG promoter activity after chIFN- α -treatment was

240 completely blocked when cells were transfected with the wild-type SOCS1. The SOCS box domain-
241 deleted SOCS1 still blocked induction of ISG promoter activity (Fig. 4B), indicating that the SOCS
242 box is not essential for inhibition of IFN signalling in DF-1 cells. Immunoblotting confirmed that the
243 SOCS box-deleted SOCS1 protein was stably expressed (Fig. 4C). We also tested the effect of
244 deletion of the kinase inhibitory region (KIR) domain. KIR-deleted SOCS1 was apparently unable to
245 block IFN-mediated induction of ISG promoter activity (results not shown). However,
246 immunoblotting showed that the KIR-deleted SOCS1 protein was unstable (Fig. 4C) so no
247 conclusion can be drawn concerning whether or not the KIR domain is essential to the ability of
248 SOCS1 to block induction of ISG promoters.

249

250 *Modulating levels of SOCS1 in CEFs and DF-1 cells affects viral yield*

251 Induction of ISG expression by $\text{chIFN-}\alpha$ is reduced by overexpression of SOCS1; conversely SOCS1
252 knockdown reverses the block to ISG induction. To determine whether modulation of SOCS1
253 expression could therefore affect virus replication, the titres of IBDV PBG98 at 16h p.i. were
254 determined for CEFs and DF-1 cells in which SOCS1 had been overexpressed or knocked down,
255 respectively (Fig. 5A). Overexpression of exogenous SOCS1 in CEFs resulted in 1 log increase in
256 IBDV titre (pfu/ml) compared with CEFs transfected with an empty vector. Conversely, knock down
257 of endogenous SOCS1 levels in DF-1 cells resulted in a corresponding decrease of viral titre
258 (approximately 1 log) at 16h p.i. compared with DF-1 cells transfected with control siRNA (Fig 5A).

259 The transfection efficiency of siSOCS1 in CEF primary cells was too low to result in significant
260 downregulation of endogenous SOCS1. Conversely, transient **overexpression SOCS1** in DF-1 cells
261 (which already have a high constitutive expression of SOCS1) did not result in significant increase
262 in the total levels of SOCS1. To overcome the latter issue, we generated a new, DF-1-derived cell line
263 stably overexpressing SOCS1 tagged with V5. We found that replication of IBDV is improved by

264 approximately 1 log compared with control (expressing the empty vector) or parental DF-1 cells
265 (data not shown).

266 Consistent with the differences in viral titre, qRT-PCR showed 37% increase in IBDV polyprotein
267 (VP4) mRNA levels following overexpression of exogenous SOCS1 in CEFs but 29% decrease
268 following knock down of endogenous SOCS1 in DF-1 cells (Fig. 5B). Western blot analysis of the
269 effects of overexpression of SOCS1 in DF-1 cells infected with IBDV (Supplementary Figure S2) also
270 demonstrated elevated levels of the IBDV VP2/3 protein but reduced levels of phosphorylated
271 STAT1 compared to untransfected control cells (total levels of STAT1 were unchanged), indicating
272 partial inhibition of virus-induced activation of STAT1 by SOCS1.

273

274 *Regulation of SOCS1 in DF-1 cells*

275 SOCS1 basal expression in DF-1 cells might be upregulated by specific transcription factors, distinct
276 from those involved in induction of ISGs. Bioinformatic analysis identified an overrepresentation of
277 CREB1 transcription factor binding sites in the promoters of genes upregulated in DF-1 cells relative
278 to CEFs and, interestingly, a CREB1 binding site (TGACGTCA) is located in the promoter proximal
279 region of chicken SOCS1 extending to within 2 bases of the transcription-starting site (Supplementary
280 Table 3). CREB1 is highly conserved in 18 bird species (data not shown) and in mammals mediates the
281 transcription of genes containing a cAMP-responsive element, including the inflammation-related: IL-
282 2, IL-6, IL-10, and TNF- α ²⁸. As well as containing a CREB1 binding site, the chicken SOCS1 promoter
283 region contains a complex array of potential regulatory elements that await functional investigation.

284 Although direct associations of transcription factors are considered an important mechanism to
285 regulate gene expression, we cannot rule out other mechanisms, such as epigenetic modifications,
286 that might independently or synergistically activate basal expression levels of chicken SOCS1 in DF-
287 1 cells. Epigenetic modifications have increasingly been associated with activation or repression of

288 innate signalling²⁹. These chromatin modifications determine how tightly DNA is wound around the
289 histones and usually involve up- or down-regulation of histone acetylases/deacetylases or
290 methyltransferases, leading to the activation of specific gene expression pathways, including innate
291 signalling^{29,30}. Histone acetylation, deacetylation, and hypermethylation have been previously
292 reported to regulate SOCS1 expression in cancer cells³¹. Analysis of microarray data presented here
293 showed that the histone deacetylases (HDAC) 9 and 11 (Supplementary Table 1) were
294 downregulated in untreated DF-1 compared with CEFs. Addition of the HDAC inhibitor sodium
295 butyrate (SB; 2mM) to cell culture medium induced significantly the expression of SOCS1 in
296 uninfected and IBDV-infected CEFs, while it had no effect on uninfected or IBDV-infected DF-1 cells
297 (Supplementary Fig. S1 online). Addition of SB to IBDV-infected CEFs increased expression levels of
298 ISGs such as IFIT5 (significantly) and MDA5, IRF7, STAT1 and Mx1 (not significantly)
299 (Supplementary Fig. S1 online).

300

301 **Discussion**

302 Infection studies in chicken cell lines are compromised by a lack of definitive understanding of the
303 chicken innate response and in particular the type I IFN response, which is the first line of defence,
304 particularly upon virus infection. Despite the high degree of evolutionary conservation, and
305 assumed similarity in overall function, there are significant differences between the innate
306 response gene repertoires of chicken (and birds in general) and mammals^{32,33}. In birds, as in
307 mammals, interferons trigger tyrosine phosphorylation and activation of members of the Janus
308 kinase (JAK) family of cytoplasmic tyrosine kinases that activate the phosphorylation of signal
309 transducers and activator of transcription (STAT)1 and STAT2, though the latter has only recently
310 been identified in birds and mapped to chicken chromosome 33 (unpublished and Galgal5)³⁴.
311 Phosphorylated STATs undergo dimerization and associate with factors such as IFN-regulatory

312 factor 9 (IRF9), though this **has not yet identified** or characterised in birds, to form the IFN-
313 stimulated gene factor 3 (ISGF3)^{35,36}. This complex then translocates to the nucleus and binds to
314 IFN-stimulated response elements (ISREs) in DNA to activate the transcription of hundreds of IFN-
315 stimulated genes (ISGs), which mediate various important biological processes in the cell including
316 antiviral and other innate response functions^{22,34,36}.

317 In a separate study, we have characterised the transcriptomic response of CEFs to recombinant
318 chIFN- α , as determined by RNA-seq and two separate microarray technologies, establishing a
319 catalogue of ISGs that can be compared to those induced by other inducers (such as dsRNA), by
320 virus infection or in different cell types⁴. Here, we have evaluated the type I IFN response of DF-1
321 cells in comparison with that of CEFs, based on microarray data validated by subsequent qRT-PCR.
322 These show that recombinant chIFN- α (or infection with an attenuated IBDV strain) can induce a
323 relatively broad range of chicken ISGs in DF-1 cells. However, the number of ISGs induced and the
324 levels of their induction were much lower in DF-1 cells compared with CEFs. Further evidence from
325 RNA-seq data (unpublished) shows lower basal levels for several ISGs, such as Mx1, IL15, IL1R1
326 and IFITM3 (data not shown), in DF-1 cells compared with CEFs. This inherently weakened
327 antiviral IFN response might, in part at least, explain the apparently improved ability of DF-1 cells,
328 compared with CEFs, to propagate several viruses.

329 Though perhaps less relevant in culture, it is noteworthy that the basal level of proinflammatory
330 gene expression was also lower in untreated DF-1 cells compared to CEFs. Genes encoding
331 proinflammatory cytokines (IL6, IL8L2), chemokines (CxCL14) and proinflammatory mediators
332 (PTGS2) are downregulated in DF-1 cells, as also reported by Kong *et al.*¹⁸.

333 The microarray data presented in this study, conducted using the 35K Affymetrix Chicken Genome
334 Array, are consistent with data from a previously reported comparison between untreated DF-1
335 and CEFs conducted with the 44K 60-mer oligonucleotide Agilent chicken microarrays by Kong *et*

336 *al.*¹⁸. Both studies demonstrated that DF-1 cells exhibit a suppression of cell death pathways,
337 altered mitochondrial related gene expression and enhanced capacity for molecular transport.
338 Upregulation of cell cycle regulatory factors (p53, E2F1, the CDKs and cyclins) and of c-src in DF-1
339 cells probably reflects their higher replication rate compared with CEFs. Our results showed
340 preferential activation of genes involved in metaphase and G2-M DNA damage checkpoints in DF-1
341 cells, which might be associated with their immortalized phenotype.

342 Here we show that the chicken ISG, SOCS1, a negative regulator of cytokine signalling in mammals,
343 is implicated in the innate response and proinflammatory phenotypes of DF-1 cells, where it might
344 also play a role in their replication and immortal phenotypes. The basal level of expression of
345 chicken SOCS1 is 16-fold higher in DF-1 cells than in CEFs, as previously reported by Kong *et al.*¹⁸.
346 Like its mammalian counterparts, chicken SOCS1 is a relatively small protein of 207 amino acids
347 (23kD); it shares high amino acid sequence identity (~65%) with mammalian orthologues.
348 Transient overexpression of chicken SOCS1 in IFN-stimulated DF-1 led to a significant relative
349 decrease in the expression of Mx1 and IFIT5; conversely, knockdown of endogenous SOCS1
350 increased their induction. Moreover, in a SOCS1-overexpressing derivative of DF-1, the IFN-
351 mediated induction of ISGs Mx1 and viperin was blocked. Like mammalian SOCS1, therefore,
352 chicken SOCS1 acts as a robust attenuator of IFN signalling to block ISG induction.

353 Although the SOCS box is generally essential for the full inhibition of IFN signalling by mammalian
354 SOCS proteins, our results demonstrate that it is not vital for the ability of chicken SOCS1 to
355 abrogate IFN signalling and subsequent induction of ISGs. In mammals, the SOCS box interacts with
356 the ubiquitin ligase complex promoting proteosomal degradation of proteins it targets. It is possible
357 that ubiquitin-mediated, proteosomal degradation of JAKs is not essential to the inhibitory
358 mechanism(s) of SOCS1 in the chicken, which might, therefore, reflect different modes of
359 interaction of SOCS1 with JAKs and overall regulation of JAK/STAT signalling.

360 The biological function of SOCS1 extends well beyond its regulatory role in the antiviral IFN response.
361 It regulates a wide range of immunological processes including dendritic cell functions³⁷, T-cell
362 differentiation³⁸, class I MHC mediated antigen processing and presentation³⁹ and IFN- γ signalling^{38,40}.
363 The observation that SOCS1 attenuates the IFN response in pluripotent human cells suggests that it
364 plays an important roles in differentiation and development⁴¹. SOCS1 also interacts directly with and
365 activates the p53 tumour suppressor through its SH2 domain, thereby regulating the process of
366 oncogene-induced senescence⁴².

367 SOCS1 is able to enter the nucleus and interact with the p65 subunit, thereby inhibiting the nuclear
368 NF- κ B signalling pathway⁴³ and inflammatory signalling pathways involving IL6⁴⁰, IL2^{44,45} and the TLR
369 signalling cascades⁴⁵. This might explain the suppression of basal level expression of proinflammatory
370 cytokines we observed in untreated DF-1 cells compared to CEFs.

371 Based on the downregulation of the histone deacetylases that we observed in DF-1 cells relative to
372 CEFs and the induction of SOCS1 expression in CEFs treated with HDAC inhibitor, it is plausible that
373 histone deacetylation in CEFs, and its downregulation in DF-1, offers a mechanism by which SOCS1
374 expression might be suppressed in CEFs and become enhanced in DF-1. We cannot rule out the role of
375 other epigenetic mechanisms influencing basal SOCS1 expression (in either CEFs or DF-1). Nor,
376 without extensive promoter analysis, can we eliminate the possibility that mutation(s) in promoter or
377 enhancer elements affect basal SOCS1 expression in DF-1 cells.

378 It is possible that reprogramming events during spontaneous immortalization of DF-1 from CEFs
379 might have indirectly activated SOCS1. It is equally plausible, however, that its overexpression was
380 selected, possibly to suppress aberrant signalling leading to apoptosis. In this context, it is interesting
381 to note (Fig. 1D) the lower basal level of expression of some ISGs (such as MX1, RSAD2 and ISG12-2) in
382 DF-1 cells compared to CEFs. Although this could be indicative of other mechanisms in play in addition
383 to elevated constitutive SOCS1, there is now recognition that low-level constitutive IFN can promote

384 “tonic signalling” to activate STAT1^{46,47}. Modulation of such “tonic signalling” by the elevated
385 constitutive levels of SOCS1 in DF-1 cells might conceivably account for the suppressed basal levels of
386 some ISGs in DF-1 cells.

387 Overexpression of SOCS1 has been reported to have a proviral effect in infection and replication for
388 viruses such as HCV, HSV-1 and vaccinia virus⁴⁸⁻⁵⁰. A recent study has also used a peptide,
389 pJAK2(1001–1013), which corresponds to the activation loop of JAK2, as a SOCS1 antagonist. The
390 antagonist enhanced innate and adaptive immune responses against a broad range of viruses
391 including herpes simplex virus, vaccinia virus, and encephalomyocarditis virus⁵¹. In this study we used
392 PBG98, an attenuated vaccine strain of IBDV, as a model avian pathogen⁵². We found that decreasing
393 the elevated levels of SOCS1 in DF-1 cells inhibited IBDV transcription and replication. Conversely,
394 increasing the levels of SOCS1 in CEFs restored the replication rate and viral yield to levels that are
395 normally observed in DF-1.

396 Altering the host innate response via modulating intracellular SOCS1 levels might offer a simple and
397 flexible solution to enhance viral propagation in culture, especially using IFN-sensitive viruses, with
398 potential applications in diagnosis and vaccine production.

399 Here we have examined the interplay between SOCS1 and the chicken IFN antiviral response in the
400 context of stimulation with recombinant IFN or IBDV infection, improving our understanding of DF-1
401 cells, which are becoming increasingly popular in studies of avian infection and innate immunity.
402 Several mammalian cell lines such Vero, HuH7.5 and BHK21, are known to be defective, by various
403 mechanisms, in intrinsic innate immunity and thereby more permissive to virus infection⁵³⁻⁵⁵. DF-1
404 therefore provide another example of IFN insufficiency, perhaps suggesting that this phenotype is
405 beneficial to the establishment of such cell lines. Those studying avian innate responses in DF-1 cells,
406 as with mammalian cells in which IFN deficiencies are better known, need to be aware of potentially
407 confounding effects due, at least in part, to their higher basal expression of SOCS1.

408

409 **Methods**

410 **Cell culture**

411 Primary CEFs, prepared by trypsin/EDTA dissociation of 10-day-old chicken embryos⁵⁶⁻⁵⁸, were
412 provided by the Institute for Animal Health (now The Pirbright Institute) from their Compton
413 Laboratory, Berkshire, UK. They were seeded in T25 flasks (Greiner Bio One; 5.6×10^6 cells/flask)
414 and cultured overnight in 5.5 ml 199 media (Gibco, Invitrogen) supplemented with 8% heat-
415 inactivated newborn bovine serum (NBCS; Gibco, Invitrogen), 10% tryptose phosphate broth (TPB;
416 Sigma), 2% nystatin (Sigma) and 0.1% penicillin and streptomycin (Gibco, Invitrogen). DF-1 were
417 propagated in Dulbecco's minimal essential medium (DMEM) (Life Technologies) supplemented
418 with 10% heat-inactivated fetal bovine serum (Life Technologies) and penicillin and streptomycin.
419 All cells were incubated at 37°C and 5% CO₂. For sodium butyrate experiments, sodium butyrate
420 (0.5-2.0mM; Sigma-Aldrich) was added directly to cells in 6-well plates and optimization
421 experiments were carried out for 18 hours in both CEFs and DF-1 cells. Samples for the mock
422 controls were treated with DMEM.

423

424 **Plasmids and luciferase reporter gene**

425 SOCS1 expression plasmid was constructed by cloning the full-length coding region of chicken
426 SOCS1 gene using *HinDIII* and *NotI* cloning sites into the eukaryotic expression vector pcDNA4, that
427 had been modified to encode an N-terminal influenza hemagglutinin (HA) epitope tag. The plasmid
428 DNA was purified from transformed bacteria and concentration determined by UV spectroscopy.
429 For luciferase reporter assays, the promoters from chicken ISGs Mx and viperin (RSAD2) were
430 amplified from CEF genomic DNA using Accuprime Pfx DNA polymerase (Invitrogen). The promoter
431 region amplified for Mx had been described previously⁵⁹; primers contained *BglII* and *MluI* sites.
432 The region amplified for viperin was -343 to -193 relative to the ATG start codon; primers

433 contained *Bam*HI and *Mlu*I sites. Both promoter fragments were inserted between the *Bam*HI and
434 *Mlu*I sites of ptkΔ(- 39)lucifer⁶⁰ producing pchMx-lucifer and pchviperin-lucifer. Full-length chicken
435 SOCS1 was also amplified from RNA using Q5 High-Fidelity DNA polymerase (New England Biolabs,
436 USA) and primers containing *Nco*I and *Eco*RI and was cloned into pEF.pLink2⁶¹. SOCS1 ΔKIR was
437 produced by amplifying the region 235-624 of SOCS1, whilst SOCS1 ΔSOCSBox was produced by
438 amplifying the region 1-495. Both fragments used *Nco*I and *Eco*RI for cloning into pEF.pLink2. All
439 clones were verified by sequencing.

440

441 **Virus infections and chIFN-α stimulation**

442 For virus infection studies, the attenuated IBDV vaccine strain strain PBG98 (propagated in CEFs⁵²),
443 a strong inducer of innate responses⁶², was used to stimulate cells. Viral titres were determined by
444 classical plaque assay in CEFs. Fully confluent DF-1 and CEFs grown in T25 flasks were washed
445 with phosphate buffer saline (PBS) and infected for 2 h with IBDV (at a multiplicity of infection, MOI,
446 of 5) or mock-infected. The inoculum was then removed and cells were washed and further
447 incubated in maintenance medium (2% fetal bovine serum) for 14h until determination of viral
448 titre. For chIFN-α stimulation experiments, recombinant chicken chIFN-α was prepared as
449 previously reported⁶³ and was added in culture media to a final concentration of 1000 U/ml.
450 Confluent cells were treated with chIFN-α or mock treated and incubated for six hours before
451 harvesting. Cells were stored at -80°C in RNAlater (Sigma) until RNA extraction.

452

453 **SOCS1 siRNA knockdown and overexpression**

454 For both siRNA knockdown and overexpression experiments, DF-1 were seeded overnight at
455 4.5×10^6 cells per plate in a 6-well plate to achieve 50% confluency. Cells were transfected with 50
456 nM of siRNA (designed and supplied by Sigma-Aldrich) coupled with JetPrime transfection reagent
457 (Polyplus Transfection SA, Illkirch, France) for 48h according to manufacturer's instruction with or

458 without a 6h 1000 units/ml chIFN- α treatment. RNA and protein samples were obtained from the
459 cells using standard techniques. Knockdown efficiency of siRNA for SOCS1 was determined at 48h
460 post transfection with qRT-PCR and western Blot. Sense (5'-CGCAGAAGAAUUGUUUCUU[dT][dT]-
461 3') or antisense (5'-AAGAAACAAUUCUUCUGCG[dT][dT]-3') siRNA were used to target chicken
462 SOCS1. Sense (5'-CGCAGAAGUUAUGUUUCUU[dT][dT]-3') or antisense (5'-
463 AAGAAACAUAACUUCUGCG[dT][dT]-3') siRNA, in which bases 9 through 11 (underlined) were
464 replaced with their complement⁶⁴, were also used as controls.

465 To investigate the possibility of "off target" effects for siSOCS1, BLAST analysis (Supplementary Fig.
466 S3 online) of siSOCS1 sequence was conducted, showing that only SOCS1 returned 100% identity
467 for 19 contiguous bases. The next best chicken hits (the only two to achieve 100% identity for 15
468 contiguous bases) were nuclear assembly factor 1 ribonucleoprotein (NAF1) and ADP-ribosylation
469 factor GTPase activating protein 3 (ARFGAP3). "Off target" effects of siSOCS1 on expression of these
470 two genes were assessed by treating DF-1 cells, 42h post-transfection (or mock-transfection) with
471 siSOCS1, with chIFN- α for a further 6h, or by infecting with PBG98 for 16h, as described above. RNA
472 was then collected and the expression of SOCS1, NAF1 and ARFGAP3 was monitored by qRT-PCR.
473 siSOCS1 reduced expression of SOCS1 by about 50% relative to mock-transfected but no reduction
474 in the expression of NAF1 or ARFGAP3 was observed (Supplementary Fig. S4 online), indicating
475 good specificity for siSOCS1.

476 For overexpression of SOCS1, a pcDNA4/HA/SOCS1 expression plasmid was used, as described
477 above. Cells were transfected with 1 μ g of a SOCS1 expression vector using the jetPrime
478 transfection reagent (Polyplus Transfection SA, Illkirch, France) according to manufacturers
479 instructions for 48 hours at 37°C and 5% CO₂. Samples for the mock controls were transfected with
480 an empty control plasmid (pcDNA4). 6h treatment of cells with chicken IFN- α was used to stimulate
481 cells before collection of samples for qRT-PCR analysis. For co-transfections, the SOCS1 expression

482 vector (0.25 µg) was combined with each siRNA as per the manufacturer's recommendations. After
483 48h, RNA and protein samples were collected for follow-up studies.

484

485 **Luciferase assay**

486 DF-1 in 12-well plates were transfected with: Mx or viperin promoter reporters (100 ng), the
487 constitutive reporter plasmid pJATlacZ (100 ng) and either plasmids driving the overexpression of
488 SOCS1 wild-type or SOCSbox deletion mutant or the control empty vector pEFPlink2 (200 ng).
489 Following recovery for 24 h, cells were either left untreated or treated with 1000 units/ml
490 recombinant chIFN-α treatment and incubated for 6 h. Luciferase assays were carried out, and data
491 were normalized using β-galactosidase measurements and expressed as fold induction over control.

492

493 **Western blot**

494 Proteins for western blots were harvested from DF-1 cultured in T75 flasks. CellLytic-M solution
495 (Sigma-Aldrich; 600µl) was added to the cell pellet, and the supernatant was collected after
496 centrifugation at 15,000xg for 15 minutes before protease inhibitor (Roche) was added. To every
497 20µl of sample, 5 µl of 4X loading buffer (Bio-Rad) was added, and the samples were heated at 60°C
498 for 5 minutes. They were then separated on a 12% sodium dodecylsulfate polyacrylamide gel,
499 alongside a protein ladder (Precision Plus Protein Dual Colour Standards, Bio-Rad). Samples (20µg)
500 were loaded for each well, and the gel was run at 150V for 2 hours. The proteins were then electro-
501 transferred to nitrocellulose membranes (Hybond-C extra, Amersham Life Science) at 100V for 1
502 hour, and blocking was carried out using 5% milk (Sigma-Aldrich) in PBS containing 0.1% Tween-
503 20 (Sigma-Aldrich) for 2 hours. After washing with PBS for five times, the membranes were either
504 incubated with mouse monoclonal anti-FLAG (M2) (Sigma-Aldrich), rabbit monoclonal anti-HA
505 (Sigma-Aldrich), or rabbit monoclonal α-tubulin (Cell signalling Technology) antibodies overnight
506 at 4°C with gentle agitation. The membranes were then washed with PBS for five times, and

507 incubated with goat anti-rabbit or donkey anti-mouse secondary antibodies (LI-COR) in the dark
508 for 1 hour. Scanning was then carried out using the Odyssey Imaging system (LI-COR). Images of
509 full-size immunoblots are shown in Supplementary Information (Supplementary Fig. S5).

510

511 **RNA extraction and processing of samples for microarray**

512 Total RNA was extracted from mock-, infected-, and IFN-stimulated DF-1 and CEFs using an RNeasy
513 kit (Qiagen) according to the manufacturer's instructions. On-column DNA digestion was performed
514 using RNase-free DNase (Qiagen) to remove contaminating genomic DNA. RNA samples were
515 quantified using a Nanodrop Spectrophotometer (Thermo Scientific) and checked for quality using
516 a 2100 Bioanalyzer (Agilent Technologies). All RNA samples had an RNA integrity number (RIN) \geq
517 9.6. RNA samples were processed for microarray using the GeneChip® 3' IVT Express Kit
518 (Affymetrix) following the manufacturer's instructions. Total RNA (100ng) was used as input and
519 quality checks were performed using the Bioanalyzer at all stages suggested by the manufacturer.
520 RNA samples were processed in batches of 12 but batch mixing was used at every stage to avoid
521 creating experimental bias. Hybridisation of RNA to chips and scanning of arrays was performed by
522 the Medical Research Council's Clinical Sciences Centre (CSC) Genomics Laboratory, Hammersmith
523 Hospital, London, UK. RNA was hybridised to GeneChip Chicken Genome Array chips (Affymetrix)
524 in a GeneChip Hybridization Oven (Affymetrix), the chips were stained and washed on a GeneChip
525 Fluidics Station 450 (Affymetrix), and the arrays were scanned in a GeneChip Scanner 3000 7G with
526 autoloader (Affymetrix).

527

528 **Microarray data analysis**

529 A two-way ANOVA (variables: cell type and treatment) adjusted with the Benjamini-Hochberg
530 multiple-testing correction (false discovery rate (FDR) of $P < 0.05$) was performed with Partek
531 Genomics Suite (v6.6, Partek) across all samples. Principal component analysis confirmed that

532 batch mixing had prevented introduction of experimental bias. Comparisons were conducted
533 between treated cells (IFN-stimulated or IBDV-infected) versus mock-treated cells for each cell line
534 (CEFs or DF-1) and between untreated DF-1 versus CEFs. The analysis cut off criteria were fold
535 change $\geq \pm 3.0$ and P -value ≤ 0.01 . The Affymetrix chicken genome arrays contain probe sets for
536 detecting transcripts from 17 avian viruses, including IBDV, allowing confirmation of viral infection.
537 Data mining and enrichment analysis was performed using the MetaCore software suite (Genego,
538 <http://thomsonreuters.com/metacore>). Enrichment analysis consisted mapping gene IDs of the
539 datasets onto gene IDs of human orthologues in entities of built-in functional ontologies
540 represented in MetaCore by pathway maps and process networks. Statistical significance was
541 measured by the number of genes that map onto a given pathway and was calculated on the basis of
542 p -value, based on hypergeometric distribution (a built-in feature of MetaCore). Full enrichment
543 analysis for the untreated DF-1 versus CEFs dataset (enrichment by gene ontology (GO) processes,
544 process networks, pathway maps and protein function) as well as a list of transcription factors
545 identified using the Metacore transcription regulation algorithm is presented in Supplementary
546 Table 2.

547 Visualisation of gene expression data was conducted with GeneSpring GX (v.13.1, Agilent
548 Technologies); GO search and grouping was performed using the PANTHER classification system
549 (<http://www.pantherdb.org/>). Fold change values for the top 45 ISGs identified in IFN-stimulated
550 CEFs were displayed in a heat map in combined data from all microarray comparisons (Hierarchical
551 Clustering) generated using the ggplot2 package within the open source R console (3.1.1). Original
552 microarray data produced or used in this study have been deposited according to the MIAME
553 guidelines in the public database ArrayExpress (<http://www.ebi.ac.uk/microarray-as/ae/>) (Acc.
554 No: E-MTAB-4028). That entry includes six CEL files, used for meta-analysis of CEFs plus or minus
555 IFN as controls for DF-1, originally deposited and available as E-MTAB-3711, as described

556 previously⁴. Tables showing ArrayExpress information for the CEL files in each entry are presented
557 as an EXCEL workbook in Supplementary Table 5.

558 *De novo* motif prediction analysis was conducted using the R console (3.1.1) and the JASPAR2014
559 (1.1.1) and TFBSTools (1.4.0) packages. Motifs obtained from databases have been sorted by match
560 score. Minimum scores of 80 and 90% have been considered as valid (Supplementary Fig. S1
561 online).

562

563 **Quantitative real-time RT PCR**

564 Quantitative real-time RT PCR was performed on RNA samples using a two-step procedure. RNA
565 was first reverse-transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen)
566 according to manufacturer's instructions. qPCR was then conducted on the cDNA in a 384-well
567 plate with a ABI-7900HT Fast qPCR system (Applied Biosystems). Mesa Green qPCR MasterMix
568 (Eurogentec) was added to the cDNA (5µl for every 2µl of cDNA). The following amplification
569 conditions were used: 95°C for 5 minutes; 40 cycles of 95°C for 15 seconds, 57°C for 20 seconds,
570 and 72°C for 20 seconds; 95°C for 15 seconds; 60°C for 15 seconds; and 95°C for 15 seconds. Primer
571 sequences for genes that were used in the study are given in Supplementary Table 4. The output Ct
572 values and dissociation curves were analysed using SDS v2.3 and RQ Manager v1.2 (Applied
573 Biosystems). Gene expression data were normalized against the housekeeping gene GAPDH, and
574 compared with the mock controls using the comparative C_T method (also referred to as the 2^{-ΔΔCT}
575 method⁶⁵). All samples were loaded in triplicate.

576

577 **Statistical analysis**

578 To determine the significance of differences between experimental groups, one-way ANOVA t-tests
579 were performed using the fold change scores with a Bonferroni multiple comparisons test or

580 unpaired t tests with Welch's correction. *P*-values were set at 0.05 ($P \leq 0.05$) unless indicated
581 otherwise. Error bars represent the standard error of the mean (SE). The correlation of expression
582 values between microarray analysis and qRT-PCR was statistically assessed by calculation of
583 Pearson's correlation coefficient using the built-in function of GraphPad Prism (v.6.0).

584

585 **Data Availability**

586 The datasets (Acc. No: E-MTAB-4028) generated and analysed during the current study are available
587 in the EMBL-EBI ArrayExpress repository ([https://www.ebi.ac.uk/arrayexpress/experiments/E-](https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-4028/)
588 [MTAB-4028/](https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-4028/); released 15 January 2016; as described in Supplementary Table 5). All other data
589 generated or analysed during this study are included in this published article (and its Supplementary
590 Information files) or are available from the corresponding author on reasonable request.

591

592 **References**

- 593 1 Hess, R. D., Weber, F., Watson, K. & Schmitt, S. Regulatory, biosafety and safety challenges
594 for novel cells as substrates for human vaccines. *Vaccine* **30**, 2715-2727,
595 doi:<http://dx.doi.org/10.1016/j.vaccine.2012.02.015> (2012).
- 596 2 Genzel, Y. Designing cell lines for viral vaccine production: Where do we stand? *Biotechnol.*
597 *J.* **10**, 728-740, doi:10.1002/biot.201400388 (2015).
- 598 3 Kallel, H. & Kamen, A. A. Large-scale adenovirus and poxvirus-vectored vaccine
599 manufacturing to enable clinical trials. *Biotechnol. J.* **10**, 741-747,
600 doi:10.1002/biot.201400390 (2015).
- 601 4 Giotis, E. S. *et al.* Chicken interferome: avian interferon-stimulated genes identified by
602 microarray and RNA-seq of primary chick embryo fibroblasts treated with a chicken type I
603 interferon (IFN- α). *Vet Res* **47**, 75, doi:[http://dx.doi.org/10.1186%2Fs13567-016-](http://dx.doi.org/10.1186%2Fs13567-016-0363-8)
604 [0363-8](http://dx.doi.org/10.1186%2Fs13567-016-0363-8) (2016).
- 605 5 Nazerian, K. An updated list of avian cell lines and transplantable tumours. *Avian Pathol.* **16**,
606 527-544, doi:10.1080/03079458708436402 (1987).
- 607 6 Brown, S. W. & Mehtali, M. The Avian EB66(R) Cell Line, Application to Vaccines, and
608 Therapeutic Protein Production. *PDA J. Pharm. Sci. Technol.* **64**, 419-425 (2010).
- 609 7 Jordan, I. *et al.* An avian cell line designed for production of highly attenuated viruses.
610 *Vaccine* **27**, 748-756, doi:10.1016/j.vaccine.2008.11.066 (2009).
- 611 8 Jordan, I. & Sandig, V. Matrix and backstage: cellular substrates for viral vaccines. *Viruses* **6**,
612 1672-1700, doi:10.3390/v6041672 (2014).
- 613 9 Foster, D. N. & Foster, L. K. Immortalized cell lines for virus growth. USA patent (1997).

- 614 10 Maas, R., van Zoelen, D., Oei, H. & Claassen, I. Replacement of primary chicken embryonic
615 fibroblasts (CEF) by the DF-1 cell line for detection of avian leucosis viruses. *Biologicals* **34**,
616 177-181, doi:10.1016/j.biologicals.2005.09.002 (2006).
- 617 11 You, S., Kong, B. W., Jeon, S. Y., Foster, D. N. & Kim, H. Dereglulation of catalase, not MnSOD,
618 is associated with necrotic death of p53-defective DF-1 cells under antimycin A-induced
619 oxidative stress. *Mol. Cells* **18**, 220-229 (2004).
- 620 12 Lee, C. W., Jung, K., Jadhao, S. J. & Suarez, D. L. Evaluation of chicken-origin (DF-1) and
621 quail-origin (QT-6) fibroblast cell lines for replication of avian influenza viruses. *J. Virol.*
622 *Methods* **153**, 22-28, doi:10.1016/j.jviromet.2008.06.019 (2008).
- 623 13 Schaefer-Klein, J. *et al.* The EV-O-derived cell line DF-1 supports the efficient replication of
624 avian leukosis-sarcoma viruses and vectors. *Virology* **248**, 305-311,
625 doi:10.1006/viro.1998.9291 (1998).
- 626 14 Laidlaw, S. M. *et al.* Genetic screen of a mutant poxvirus library identifies an ankyrin repeat
627 protein involved in blocking induction of avian type I interferon. *J. Virol.* **87**, 5041-5052,
628 doi:10.1128/JVI.02736-12 (2013).
- 629 15 Levy, A. M. *et al.* Marek's disease virus Meq transforms chicken cells via the v-Jun
630 transcriptional cascade: a converging transforming pathway for avian oncoviruses. *Proc.*
631 *Natl. Acad. Sci. U S A* **102**, 14831-14836, doi:10.1073/pnas.0506849102 (2005).
- 632 16 Rekha, K., Sivasubramanian, C., Chung, I. M. & Thiruvengadam, M. Growth and replication of
633 infectious bursal disease virus in the DF-1 cell line and chicken embryo fibroblasts. *Biomed.*
634 *Res. Int.* **2014**, 494835, doi:10.1155/2014/494835 (2014).
- 635 17 Tiwari, A., Patnayak, D. P., Chander, Y. & Goyal, S. M. Permissibility of different cell types for
636 the growth of avian metapneumovirus. *J. Virol. Methods* **138**, 80-84,
637 doi:10.1016/j.jviromet.2006.07.020 (2006).
- 638 18 Kong, B.-W. *et al.* Genome-wide differential gene expression in immortalized DF-1 chicken
639 embryo fibroblast cell line. *BMC Genomics* **12**, doi:10.1186/1471-2164-12-571 (2011).
- 640 19 Kim, H. *et al.* Alterations in p53 and E2F-1 function common to immortalized chicken
641 embryo fibroblasts. *Oncogene* **20**, 2671-2682, doi:10.1038/sj.onc.1204378 (2001).
- 642 20 Kim, H. *et al.* Necrotic cell death by hydrogen peroxide in immortal DF-1 chicken embryo
643 fibroblast cells expressing deregulated MnSOD and catalase. *Biochim. Biophys. Acta* **1540**,
644 137-146 (2001).
- 645 21 Himly, M., Foster, D. N., Bottoli, I., Iacovoni, J. S. & Vogt, P. K. The DF-1 chicken fibroblast cell
646 line: transformation induced by diverse oncogenes and cell death resulting from infection
647 by avian leukosis viruses. *Virology* **248**, 295-304, doi:10.1006/viro.1998.9290 (1998).
- 648 22 Qu, H. *et al.* The differential antiviral activities of chicken interferon alpha (ChIFN-alpha)
649 and ChIFN-beta are related to distinct interferon-stimulated gene expression. *PLoS One* **8**,
650 e59307, doi:10.1371/journal.pone.0059307 (2013).
- 651 23 Mi, H., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. Large-scale gene function analysis
652 with the PANTHER classification system. *Nature Protocols* **8**, 1551 - 1566,
653 doi:10.1038/nprot.2013.092 (2013).
- 654 24 Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune
655 regulation. *Nat. Rev. Immunol.* **7**, 454-465, doi:10.1038/nri2093 (2007).
- 656 25 Yasukawa, H. *et al.* The JAK-binding protein JAB inhibits Janus tyrosine kinase activity
657 through binding in the activation loop. *EMBO J.* **18**, 1309-1320,
658 doi:10.1093/emboj/18.5.1309 (1999).
- 659 26 Narazaki, M. *et al.* Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its
660 suppression of interleukin 6 signaling. *Proc. Natl. Acad. Sci. U S A* **95**, 13130-13134 (1998).

- 661 27 Babon, J. J., Sabo, J. K., Zhang, J. G., Nicola, N. A. & Norton, R. S. The SOCS box encodes a
662 hierarchy of affinities for Cullin5: implications for ubiquitin ligase formation and cytokine
663 signalling suppression. *J. Mol. Biol.* **387**, 162-174 (2009).
- 664 28 Wen, A. Y., Sakamoto, K. M. & Miller, L. S. The role of the transcription factor CREB in
665 immune function. *J. Immunol.* **185**, 6413-6419, doi:10.4049/jimmunol.1001829 (2010).
- 666 29 Lee, J. *et al.* Activation of innate immunity is required for efficient nuclear reprogramming.
667 *Cell* **151**, 547-558, doi:10.1016/j.cell.2012.09.034 (2012).
- 668 30 Gao, S. M. *et al.* Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT
669 signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in
670 myeloproliferative neoplasms. *Exp. Hematol.* **41**, 261-270 e264,
671 doi:10.1016/j.exphem.2012.10.012 (2013).
- 672 31 Gao, S.-m. *et al.* Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT
673 signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in
674 myeloproliferative neoplasms. *Exp. Hematol.* **41**, 261-270,
675 doi:10.1016/j.exphem.2012.10.012 (2013).
- 676 32 Hayashi, T. *et al.* Chicken MDA5 senses short double-stranded RNA with implications for
677 antiviral response against avian influenza viruses in chicken. *J. Innate Immun.* **6**, 58-71,
678 doi:10.1159/000351583 (2014).
- 679 33 Liniger, M., Summerfield, A., Zimmer, G., McCullough, K. C. & Ruggli, N. Chicken cells sense
680 influenza A virus infection through MDA5 and CARDIF signaling involving LGP2. *J. Virol.* **86**,
681 705-717, doi:10.1128/JVI.00742-11 (2012).
- 682 34 Karpala, A. J., Lowenthal, J. W. & Bean, A. G. Identifying innate immune pathways of the
683 chicken may lead to new antiviral therapies. *Vet. Immunol. Immunopathol.* **148**, 100-109,
684 doi:10.1016/j.vetimm.2011.05.031 (2012).
- 685 35 May, D. L., Grant, C. E. & Deeley, R. G. Cloning and promoter analysis of the chicken
686 interferon regulatory factor-3 gene. *DNA Cell Biol.* **19**, 555-566,
687 doi:10.1089/104454900439782 (2000).
- 688 36 Masuda, Y. *et al.* Biological effects of chicken type III interferon on expression of interferon-
689 stimulated genes in chickens: comparison with type I and type II interferons. *J. Vet. Med. Sci.*
690 **74**, 1381-1386 (2012).
- 691 37 Zhang, J. *et al.* Enhanced activation of human dendritic cells by silencing SOCS1 and
692 activating TLRs simultaneously. *Cancer Immunol. Immunother.* **61**, 1653-1661,
693 doi:10.1007/s00262-012-1218-4 (2012).
- 694 38 Hashimoto, M. *et al.* SOCS1 regulates type I/type II NKT cell balance by regulating
695 IFN γ signaling. *Int. Immunol.* **23**, 165-176, doi:10.1093/intimm/dxq469 (2011).
- 696 39 Turnley, A. M., Starr, R. & Bartlett, P. F. Failure of sensory neurons to express class I MHC is
697 due to differential SOCS1 expression. *J. Neuroimmunol.* **123**, 35-40 (2002).
- 698 40 Croker, B. A. *et al.* SOCS3 negatively regulates IL-6 signaling in vivo. *Nat. Immunol.* **4**, 540-
699 545, doi:10.1038/ni931 (2003).
- 700 41 Hong, X.-X. & Carmichael, G. G. Innate immunity in pluripotent human cells attenuated
701 response to interferon-beta. *J. Biol. Chem.* **288**, 16196-16205,
702 doi:10.1074/jbc.M112.435461 (2013).
- 703 42 Mallette, F. A., Calabrese, V., Ilangumaran, S. & Ferbeyre, G. SOCS1, a novel interaction
704 partner of p53 controlling oncogene-induced senescence. *Aging (Albany NY)* **2**, 445-452
705 (2010).
- 706 43 Strebovsky, J., Walker, P., Lang, R. & Dalpke, A. H. Suppressor of cytokine signaling 1
707 (SOCS1) limits NF κ B signaling by decreasing p65 stability within the cell nucleus.
708 *FASEB J.* **25**, 863-874, doi:10.1096/fj.10-170597 (2011).

709 44 Sporri, B., Kovanen, P. E., Sasaki, A., Yoshimura, A. & Leonard, W. J. JAB/SOCS1/SSI-1 is an
710 interleukin-2-induced inhibitor of IL-2 signaling. *Blood* **97**, 221-226 (2001).

711 45 Fujimoto, M. & Naka, T. SOCS1, a Negative Regulator of Cytokine Signals and TLR
712 Responses, in Human Liver Diseases. *Gastroenterol. Res. Pract.* **2010**,
713 doi:10.1155/2010/470468 (2010).

714 46 Gough, D. J., Messina, N. L., Clarke, C. J., Johnstone, R. W. & Levy, D. E. Constitutive type I
715 interferon modulates homeostatic balance through tonic signaling. *Immunity* **36**, 166-174,
716 doi:10.1016/j.immuni.2012.01.011 (2012).

717 47 McComb, S. *et al.* Type-I interferon signaling through ISGF3 complex is required for
718 sustained Rip3 activation and necroptosis in macrophages. *Proc Natl Acad Sci U S A* **111**,
719 E3206-3213, doi:10.1073/pnas.1407068111 (2014).

720 48 Ahmed, C. M. *et al.* Enhancement of antiviral immunity by small molecule antagonist of
721 suppressor of cytokine signaling. *J. Immunol.* **185**, 1103-1113,
722 doi:10.4049/jimmunol.0902895 (2010).

723 49 Reichard, A. C., Cheemarla, N. R. & Bigley, N. J. SOCS1/3 expression levels in HSV-1-infected,
724 cytokine-polarized and -unpolarized macrophages. *J. Interferon Cytokine Res.* **35**, 32-41,
725 doi:10.1089/jir.2013.0070 (2015).

726 50 Xu, G. *et al.* MiR-221 accentuates IFNs anti-HCV effect by downregulating SOCS1 and SOCS3.
727 *Virology* **462-463**, 343-350, doi:10.1016/j.virol.2014.06.024 (2014).

728 51 Ahmed, C. M., Larkin, J., 3rd & Johnson, H. M. SOCS1 Mimetics and Antagonists: A
729 Complementary Approach to Positive and Negative Regulation of Immune Function. *Front.*
730 *Immunol.* **6**, 183, doi:10.3389/fimmu.2015.00183 (2015).

731 52 Brown, M. D. & Skinner, M. A. Coding sequences of both genome segments of a European
732 'very virulent' infectious bursal disease virus. *Virus Res.* **40**, 1-15 (1996).

733 53 Mosca, J. D. & Pitha, P. M. Transcriptional and posttranscriptional regulation of exogenous
734 human beta interferon gene in simian cells defective in interferon synthesis. *Mol. Cell Biol.*
735 **6**, 2279-2283 (1986).

736 54 Blight, K. J., McKeating, J. A. & Rice, C. M. Highly permissive cell lines for subgenomic and
737 genomic hepatitis C virus RNA replication. *J. Virol.* **76**, 13001-13014 (2002).

738 55 Otsuki, K., Maeda, J., Yamamoto, H. & Tsubokura, M. Studies on avian infectious bronchitis
739 virus (IBV). III. Interferon induction by and sensitivity to interferon of IBV. *Arch. Virol.* **60**,
740 249-255 (1979).

741 56 Cotter, C. A., Earl, P. L., Wyatt, L. S. & Moss, B. Preparation of Cell Cultures and Vaccinia
742 Virus Stocks. *Curr Protoc Microbiol* **39**, 14A 13 11-18,
743 doi:10.1002/9780471729259.mc14a03s39 (2015).

744 57 Earl, P. L., Cooper, N., Wyatt, L. S., Moss, B. & Carroll, M. W. Preparation of cell cultures and
745 vaccinia virus stocks. *Curr Protoc Protein Sci* **Chapter 5**, Unit5 12,
746 doi:10.1002/0471140864.ps0512s13 (2001).

747 58 Purchase, H. G. in *Isolation and Identification of Avian Pathogens* (eds C. H. Hitchner, H. G.
748 Domermuth, H. G. Purchase, & J. E. Williams) (American Association of Avian Pathologists,
749 1980).

750 59 Schumacher, B., Bernasconi, D., Schultz, U. & Staeheli, P. The chicken Mx promoter contains
751 an ISRE motif and confers interferon inducibility to a reporter gene in chick and monkey
752 cells. *Virology* **203**, 144-148, doi:10.1006/viro.1994.1464 (1994).

753 60 King, P. & Goodbourn, S. The beta-interferon promoter responds to priming through
754 multiple independent regulatory elements. *J. Biol. Chem.* **269**, 30609-30615 (1994).

755 61 Marais, R., Light, Y., Paterson, H. F. & Marshall, C. J. Ras recruits Raf-1 to the plasma
756 membrane for activation by tyrosine phosphorylation. *EMBO J.* **14**, 3136-3145 (1995).

- 757 62 Aricibasi, M., Jung, A., Heller, E. D. & Rautenschlein, S. Differences in genetic background
758 influence the induction of innate and acquired immune responses in chickens depending
759 on the virulence of the infecting infectious bursal disease virus (IBDV) strain. *Vet. Immunol.*
760 *Immunopathol.* **135**, 79-92, doi:10.1016/j.vetimm.2009.11.005 (2010).
- 761 63 Buttigieg, K. *et al.* Genetic screen of a library of chimeric poxviruses identifies an ankyrin
762 repeat protein involved in resistance to the avian type I interferon response. *J Virol* **87**,
763 5028-5040, doi:10.1128/JVI.02738-12 (2013).
- 764 64 Buehler, E., Chen, Y. C. & Martin, S. C911: A bench-level control for sequence specific siRNA
765 off-target effects. *PLoS One* **7**, e51942, doi:10.1371/journal.pone.0051942 (2012).
- 766 65 Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR.
767 *Nucleic Acids Res.* **29**, e45 (2001).
768

769

770 **Acknowledgements**

771 Our thanks go to Stephen Laidlaw, Xin Chua, Io Hong Cheong and Philippe Rasclé for their technical
772 assistance. This research was undertaken with the financial support of the Biotechnology and
773 Biological Sciences Research Council (<http://www.bbsrc.ac.uk>) via Strategic LoLa BB/K002465/1
774 (“Developing Rapid Responses to Emerging Virus Infections of Poultry, DRREVIP”) and grant
775 BB/H005323/1 (“Correlation of immunogenicity with microarray analysis of vector mutants to
776 improve live recombinant poxvirus vaccines in poultry”).

777

778 **Author Contributions**

779 E.S.G. designed and performed the experiments and wrote the manuscript. R.R.C. performed part of
780 microarray work. C.S.R. generated luciferase reporter plasmids, performed luciferase assays and
781 wrote the manuscript. A.N. performed promoter analysis and wrote the manuscript. S.G. designed
782 experiments and wrote the manuscript and M.A.S. analysed data, designed microarray experiments
783 and wrote the manuscript.

784

785 **Additional Information**

786

787 **Competing financial interests:** The authors declare no competing financial interests.

788

789 **Figure Legends**

790 **Figure 1: Microarray analysis shows that DF-1 have an attenuated innate response compared**

791 **with CEFs. (A)** Results from the microarray comparison between untreated DF-1 and CEFs. Pie charts

792 represent the number of up- and down- regulated transcripts associated with different biological

793 processes, assessed by Gene Ontology (GO) search and summarized according to their functions

794 (PANTHER classification system). Scatter plots and Venn diagrams, showing extent of differential gene

795 expression (Log2) and numbers of genes differentially regulated, respectively, in comparisons

796 between CEFs and DF-1, either **(B)** treated with recombinant chIFN α (1000 units/ml, 6h), or **(C)**

797 infected with IBDV (MOI: 5, 16h). Scatter plots were generated using the Genespring scatter plot tool.

798 Scatter plots show DF-1 (Y-axis) versus CEFs (X-axis) cells. The scale on the X- and Y-axis indicate

799 expression levels (log2) and change in gene expression represented as a gradient of blue and red color

800 for low- and high-expression intensity respectively. **(D)** Cluster analysis and heat-map showing

801 differential expression of the top 45 ISGs (|fold change| ≥ 3.0 and FDR ≤ 0.01) as identified in CEFs

802 following chIFN α stimulation. **ISGs were ranked according to hierarchically.** Columns represent five

803 comparisons, left to right: IBDV-infected CEFs and DF-1, chIFN α -stimulated CEFs and DF-1 (each

804 compared to their respective mock-treated control) and mock-treated DF-1 compared to mock-

805 treated CEFs. Fold change in gene expression is represented by a blue (down-regulated) to red (up-

806 regulated) colour intensity gradient. **(E)** Microarray expression data (log2 normalised intensity values

807 \pm Standard Deviation) for SOCS1 in, IBDV-infected, chIFN α -treated or mock-treated CEFs or DF-1.

808

809 **Figure 2: Comparison of median differential expression levels for 10 selected transcripts**

810 **determined by microarray and qRT-PCR analysis.** Plots show log₁₀ expression fold change for the

811 selected genes under five different conditions: **(A)** Mock-treated DF-1 versus CEFs, **(B)** chIFN α -

812 stimulated versus mock-treated CEFs, **(C)** chIFN α -stimulated versus mock-treated DF-1, **(D)** IBDV-
813 infected versus mock-treated CEFs and **(E)** IBDV-infected versus mock-treated DF-1. Pearson
814 correlation coefficients (r) are shown in the lower right corner of each plot.

815

816 **Figure 3: Relative suppression or induction of ISG transcription by overexpression or**
817 **knockdown, respectively, of SOCS1. (A-C)** DF-1 were transfected with control siRNA or siRNA
818 specific for SOCS1 for 42h and mock-treated or treated with chIFN- α (1000 units/ml) for 6h. **(D-F)**
819 DF-1 were transfected with either empty vector or an HA-tagged SOCS1 expression plasmid (SOCS1p)
820 for 42h and and mock-treated or treated with chIFN- α (1000 units/ml) for 6h. Extracted total RNA
821 was subjected to reverse transcription followed by quantitative PCR using specific primer sets for
822 SOCS1 (A and D), Mx1 (B and E), IFIT5 (C and F) normalized against GAPDH (using the $\Delta\Delta Ct$ method).
823 Data in A-F are representative from three independent experiments. One-way (A-F) Anova with
824 Bonferroni *posthoc* test were used to analyse the data. *, $P < 0.05$, ***, $P < 0.001$, ****, $P < 0.0001$. **(G)** &
825 **(H)** Immunoblots confirming expression of exogenous HA-tagged SOCS1 following transfection of DF-
826 1 with either pcDNA4 (empty vector) or pcDNA4 expressing HA-tagged SOCS1 **(G)** and silencing of
827 SOCS1 following transfection of DF-1 with the Flag-tagged SOCS1 construct and either siRNA for
828 SOCS1 or a control siRNA **(H)**. Panels **(G)** and **(H)** show cropped images of the immunoblots; full-
829 length blots are presented in Supplementary Fig. S5 online.

830

831 **Figure 4: The SOCS box is not essential for ChSOCS1 inhibition of JAK/STAT signalling in DF-1.**

832 **(A)** Schematic representation of the architecture of SOCS1 protein, expression plasmids encoding
833 wild-type (SOCS1 WT) and SOCS box deletion mutant (SOCS1 Δ BOX) and alignment of sequences (in
834 boxes) of the KIR motif and the SOCS box domain of human, mouse and chicken SOCS1 proteins. **(B)**
835 Luciferase reporter gene assay in DF-1 for chicken Mx1 and viperin promoters following transient
836 transfection expression plasmids SOCS1 WT and SOCS1 Δ BOX, each with and without chIFN- α

837 treatment. Two-way Anova with Bonferroni *posthoc* test were used to analyse the data. *, $P < 0.05$, **, P
838 < 0.01 , ***, $P < 0.001$, ****, $P < 0.0001$. **(C)** Immunoblot confirming expression of Flag-tag in Flag-tagged
839 expression plasmids encoding for wild-type (WT) SOCS1 and SOCS box deletion mutant (Δ BOX). No
840 band was observed when DF-1 were transfected with SOCS1 KIR deletion mutant (Δ KIR) plasmid.
841 Panel **(C)** shows cropped images of the immunoblots; full-length blots are presented in Supplementary
842 Fig. S5 online.

843

844 **Figure 5: Modulating levels of SOCS1 in CEFs and DF-1 regulates viral RNA expression and virus**
845 **yield. (A)** Titres of IBDV PBG98 recovered from CEFs and DF-1 after transient transfection with a
846 SOCS1 expression plasmid or siSOCS1, respectively. Virus titres are the sum of cell-associated and
847 extracellular virus, determined by plaque assay on CEFs (Mean \pm SEM). **(B)** Fold change (percent) of
848 IBDV VP4 RNA levels in CEFs and DF-1 after transient transfection with a SOCS1 expression plasmid
849 or siSOCS1, respectively. Virus titres and viral RNA levels were compared with those from cells
850 transfected with empty vectors or control siRNA, as appropriate. Data are representative from three
851 independent experiments. An unpaired t-test with Welch's correction (Two-tailed) was used to
852 analyse the data. **, $P < 0.01$, ****, $P < 0.0001$.

853

854 **Tables**

855 **Table 1:** Top 10 statistically significant GeneGo pathway maps associated with upregulated genes
 856 in the comparison of unstimulated DF-1 versus CEF cells.

857

Pathways	<i>p</i> -value	Molecules
The metaphase checkpoint	2.831E-17	Nek2A, BUB1, Rod, MIS12, Aurora-A, PLK1, HEC, CDCA1, CDC20, CENP-C, CENP-F, Zwilch, ZW10, Survivin, CENP-E, BUBR1
Role of APC in cell cycle regulation	1.246E-13	Nek2A, BUB1, Tome-1, Geminin, Cyclin A, Aurora-A, PLK1, CDC20, Securin, ORC1L, CDK1 (p34), CKS1, BUBR1
Spindle assembly and chromosome separation	1.287E-10	Nek2A, Importin (karyopherin)-alpha, TPX2, Aurora-A, KNSL1, HEC, CDC20, Separase, ZW10, Securin, CDK1 (p34)
Chromosome condensation in prometaphase	4.671E-10	BRRN1, CAP-H/H2, CAP-G, Cyclin A, CAP-G/G2, Aurora-A, CAP-E, TOP2, CDK1 (p34)
Start of DNA replication in early S phase	1.895E-09	Cdt1, RPA3, Geminin, MCM3, E2F1, MCM10, ORC6L, ASK (Dbf4), ORC1L, MCM5
DNA damage_Role of Brca1 and Brca2 in DNA repair	1.887E-08	ATR, Rad51, MSH6, Bard1, Brca1/Bard1, Brca1, p53BP1, FANCL, Brca2
Transition and termination of DNA replication	1.835E-07	TOP2 alpha, Bard1, Cyclin A, Brca1/Bard1, Brca1, TOP2, FEN1, CDK1 (p34)
Nucleocytoplasmic transport of CDK/Cyclins	4.285E-07	Importin (karyopherin)-alpha, Cyclin A, CRM1, Cyclin D3, Cyclin D, CDK1 (p34)
Role of Nek in cell cycle regulation	7.845E-06	Nek2A, Tubulin beta, TPX2, NEK7, Aurora-A, HEC, CDK1 (p34)
DNA damage_ATM/ATR regulation of G1/S checkpoint	7.845E-06	ATR, BLM, Bard1, Cyclin A, Brca1, FANCL, Cyclin D

858

859 **Table 2:** Top 10 statistically significant GeneGo pathway maps associated with down regulated
 860 genes in the comparison of unstimulated DF-1 versus CEF cells.


861
 862

Pathways	p-value	Molecules
ECM remodeling	7.669E-09	Matrilysin (MMP-7), Collagen II, MMP-13, TIMP3, Stromelysin-2, Collagen IV, SERPINE2, Nidogen, Osteonectin, EGFR, LAMA4, MMP-9, PLAU (UPA), Versican, Collagen III
Development_Regulation of epithelial-to-mesenchymal transition (EMT)	2.337E-08	IL-1RI, VE-cadherin, E-cadherin, TGF-beta 2, Caldesmon, Tropomyosin-1, PDGF-R-alpha, TGF-beta 3, Claudin-1, WNT, SLUG, EGFR, MMP-9, Frizzled, EDNRA, Bcl-2
Stimulation of TGF-beta signaling	1.363E-06	COX-2 (PTGS2), E-cadherin, TGF-beta 2, EGR1, TGF-beta, Tropomyosin-1, PI3K reg class IA (p85-alpha), TGF-beta 3, SLUG, Keratin 19, MMP-9, Tropomyosin-2
Cytoskeleton remodeling	3.722E-06	Keratin 5/14, PPL(periplakin), Keratin 7, Tubulin alpha, Trichoplein, Keratin 14, Plakophilin 2, Keratin 19, Keratin 5, Desmoplakin
FGF signalling	6.040E-06	E-cadherin, HBP17, PI3K reg class IA (p85), Glypican-1, PI3K cat class IA, FGF7, FGFR2, MMP-9, PLAU (UPA), FGF10, Alpha-catenin
Cell adhesion_Plasmin signalling	2.285E-05	TGF-beta 2, PI3K cat class IA, MMP-13, PI3K reg class IA, Collagen IV, LEKTI, TFPI-2, PLAU (UPA), Neuroserpin
Immune response_HMGB1/RAGE signaling pathway	2.569E-05	IL-6, PI3K reg class IA (p85), PI3K cat class IA, VCAM1, PI3K reg class IA (p85-alpha), IL1RN, Tissue factor, Secretogranin II, TLR2, MEF2C, MYOG
Development_TGF-beta-dependent induction of EMT via RhoA, PI3K and ILK.	3.925E-05	E-cadherin, TGF-beta 2, Caldesmon, PI3K reg class IA (p85), Tropomyosin-1, PI3K cat class IA, TGF-beta 3, Claudin-1, Actin, SLUG
Cell-matrix glycoconjugates	4.658E-05	CCL5, Fibulin-2, Fibulin-1, NCAM1, CRTLI, Tenascin-C, Elastin, MMP-9, Versican
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling	5.177E-05	p15, Matrilysin (MMP-7), PI3K cat class IA, Alpha-actinin, MMP-13, PI3K reg class IA, Collagen IV, p21, MELC, MYLK1, WNT, WIF1, Actin, PLAU (UPA), MLCK, Frizzled



863

A Untreated cells (Mock DF-1 v. Mock CEF)



Upregulated transcripts: 878





Down regulated transcripts: 1720




B chIFN α -stimulated cells (Treated v. Mock)




C IBDV-infected cells (Treated v. Mock)












D Interferon-stimulated genes (ISGs)




E SOCS1 (Suppressor of Cytokine Signalling 1)









KIR region SOCS box

Human ...SSTHFRTFRSQAD...KVLVTPLRKVRVQPLQELCRKSIVKTFGRENLNQIPLNPVLKDYLSFFPFI
Mouse ...GDTHFRTFRSHAD...RMLGAPLRQRRVRPLQELCRQRIVATVGRENLARIPLNPVLRDYLSSFFPFI
Chicken...GDTHFRTFRSHSD...RMLGAPLRQRRVRPLQELCRQRIVA AVGRENLARIPLNPVLRDYLSSFFPFI

